BR112015022571A2 - método de tratamento de esteatose hepática - Google Patents

método de tratamento de esteatose hepática

Info

Publication number
BR112015022571A2
BR112015022571A2 BR112015022571A BR112015022571A BR112015022571A2 BR 112015022571 A2 BR112015022571 A2 BR 112015022571A2 BR 112015022571 A BR112015022571 A BR 112015022571A BR 112015022571 A BR112015022571 A BR 112015022571A BR 112015022571 A2 BR112015022571 A2 BR 112015022571A2
Authority
BR
Brazil
Prior art keywords
treatment method
liver steatosis
patient
steatosis treatment
treating
Prior art date
Application number
BR112015022571A
Other languages
English (en)
Inventor
Chen Chihming
Liu Sheng-Yung
Wen Wu-Che
Original Assignee
Golden Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Golden Biotechnology Corp filed Critical Golden Biotechnology Corp
Publication of BR112015022571A2 publication Critical patent/BR112015022571A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

resumo “método de tratamento de esteatose hepática” a presente invenção se refere a um método de tratamento, inibição e / ou prevenção de doença hepática em um paciente em sua necessidade, que compreende a administração de uma quantidade eficaz de um composto ciclohexenona da fórmula (i) a seguir ao referido paciente, (estruturalmente representado).
BR112015022571A 2013-03-13 2013-11-26 método de tratamento de esteatose hepática BR112015022571A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/801,697 US20140274979A1 (en) 2013-03-13 2013-03-13 Method for the treatment of fatty liver disease
PCT/US2013/072092 WO2014158242A1 (en) 2013-03-13 2013-11-26 Method for the treatment of fatty liver disease

Publications (1)

Publication Number Publication Date
BR112015022571A2 true BR112015022571A2 (pt) 2017-07-18

Family

ID=51529924

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022571A BR112015022571A2 (pt) 2013-03-13 2013-11-26 método de tratamento de esteatose hepática

Country Status (12)

Country Link
US (4) US20140274979A1 (pt)
EP (1) EP2968217B1 (pt)
JP (1) JP6377713B2 (pt)
KR (1) KR20150130352A (pt)
CN (1) CN105209028B (pt)
BR (1) BR112015022571A2 (pt)
ES (1) ES2730739T3 (pt)
HK (1) HK1216614A1 (pt)
MX (1) MX2015012455A (pt)
SG (1) SG11201507181YA (pt)
TW (1) TWI631943B (pt)
WO (1) WO2014158242A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI711464B (zh) * 2015-11-19 2020-12-01 欣耀生醫股份有限公司 預防或治療脂肪肝、保護肝功能、或改善脂肪肝引起的肝病變或其他相關病症之組合物及方法
CN107343890A (zh) * 2016-05-06 2017-11-14 北京大学 牛樟芝及单体羊毛甾烷32在防治非酒精性脂肪肝中的应用
SG11201810082VA (en) * 2016-05-13 2018-12-28 Golden Biotechnology Corp Methods and compositions for treating advanced stage non-small cell lung cancer
WO2018057897A1 (en) 2016-09-23 2018-03-29 Ghosh Arun K Anti-cancer agents and preparation thereof
EP3930724A4 (en) * 2019-02-25 2022-11-23 Arjil Biotech Holding Company Limited METHOD AND COMPOSITION FOR INHIBITING VIRAL INFECTION

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101516835A (zh) * 2006-07-19 2009-08-26 俄亥俄州立大学研究基金会 选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途
AU2007275736A1 (en) * 2006-07-19 2008-01-24 Osurf (Ohio State University Research Foundation) Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
JP2008260695A (ja) * 2007-04-10 2008-10-30 Nissei Bio Kk 肝障害抑制剤
TWI394573B (zh) * 2007-06-14 2013-05-01 Golden Biotechnology Corp Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for Liver Protection
CN101785793A (zh) * 2009-01-23 2010-07-28 伟诚生物科技有限公司 保护肝脏及增进身体免疫调节功能的樟芝萃取物胶囊用途
CN102892760B (zh) * 2010-05-19 2014-05-07 兴和株式会社 非醇性脂肪性肝炎的预防和/或治疗剂
US8309611B2 (en) * 2010-09-20 2012-11-13 Golden Biotechnology Corporation Methods and compositions for treating lung cancer

Also Published As

Publication number Publication date
CN105209028B (zh) 2019-06-14
EP2968217A4 (en) 2016-11-02
CN105209028A (zh) 2015-12-30
US10959963B2 (en) 2021-03-30
WO2014158242A1 (en) 2014-10-02
US20200093757A1 (en) 2020-03-26
US20140274979A1 (en) 2014-09-18
EP2968217A1 (en) 2016-01-20
SG11201507181YA (en) 2015-10-29
MX2015012455A (es) 2016-04-07
US20170304224A1 (en) 2017-10-26
KR20150130352A (ko) 2015-11-23
TWI631943B (zh) 2018-08-11
TW201440759A (zh) 2014-11-01
ES2730739T3 (es) 2019-11-12
JP6377713B2 (ja) 2018-08-22
EP2968217B1 (en) 2019-03-13
US20210177775A1 (en) 2021-06-17
HK1216614A1 (zh) 2016-11-25
JP2016512238A (ja) 2016-04-25

Similar Documents

Publication Publication Date Title
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
BR112019001794A2 (pt) composição de cannabis
BR112017024684A2 (pt) compostos coagonistas de glucagon e glp-1
BR112015022197A2 (pt) tratamento de cataplexia
BR112015005117A2 (pt) métodos de tratamento da doença de alzheimer e suas composições farmacêuticas
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
CL2015001154A1 (es) Tratamiento o prevencion de eventos cardiovasculares mediante la administracion de un derivado de colchicina.
BR112015009168A2 (pt) composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112015022465A2 (pt) método para tratamento não-tóxico para síndrome de abstinência de drogas
BR112016022593A2 (pt) composições e métodos para modular a expressão do fator b do complemento
BR112015022571A2 (pt) método de tratamento de esteatose hepática
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112015021429A2 (pt) compostos antivirais
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
BR112021018924A2 (pt) Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento
BR112013022147A2 (pt) composto, composição farmacêutica, método de inibição da pask, método de tratamento de uma doença, método para alcançar um efeito em um paciente e método de tratamento de uma doença mediada pela pask
BR112018071467A2 (pt) método de tratamento ou prevenção de patologias hepáticas
BR112017023164A2 (pt) composto, e, método de prevenir e/ou tratar a esteato-hepatite não alcoólica em um indivíduo em necessidade do mesmo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]